AGENT SKILL

bio-crispr-screens-jacks-analysis

Runs JACKS (Joint Analysis of CRISPR/Cas9 Knockout Screens; Allen et al 2019 Genome Research) which models per-sgRNA log-fold-change as the product of a treatment-dependent gene-essentiality term and a treatment-independent guide-efficacy term. Covers the Bayesian decomposition math, the hierarchical efficacy prior shared across screens performed with the same library, when JACKS outperforms MAGeCK (multi-screen joint analysis, libraries with broad efficacy variance) and when it does not (single screen, novel libraries with no prior efficacy), library-reuse efficacy transfer, downstream essentiality interpretation, and the 2.5x sample-size reduction enabled by efficacy-aware testing. Use when running multiple screens with the same library, when guide-level noise is suspected to dominate per-gene signal, when reusing published essentiality reference screens for efficacy priors, or when comparing screens performed across cell lines that share library but differ biologically.

License 许可
Apache-2.0
最近更新
2026-10-12
Stars
★ 2
Forks
0

01 前言 Front Matter

name
bio-crispr-screens-jacks-analysis
tool_type
python
description
Runs JACKS (Joint Analysis of CRISPR/Cas9 Knockout Screens; Allen et al 2019 Genome Research) which models per-sgRNA log-fold-change as the product of a treatment-dependent gene-essentiality term and a treatment-independent guide-efficacy term. Covers the Bayesian decomposition math, the hierarchical efficacy prior shared across screens performed with the same library, when JACKS outperforms MAGeCK (multi-screen joint analysis, libraries with broad efficacy variance) and when it does not (single screen, novel libraries with no prior efficacy), library-reuse efficacy transfer, downstream essentiality interpretation, and the 2.5x sample-size reduction enabled by efficacy-aware testing. Use when running multiple screens with the same library, when guide-level noise is suspected to dominate per-gene signal, when reusing published essentiality reference screens for efficacy priors, or when comparing screens performed across cell lines that share library but differ biologically.
primary_tool
JACKS

02 资源文件 2

03 SKILL.md 正文

Version Compatibility

Reference examples tested with: JACKS 0.2 (felicityallen/JACKS; checked 2026-09-16), pandas 2.2+, numpy 1.26+, scipy 1.12+, matplotlib 3.8+.

Before using code patterns, verify installed versions match. If versions differ:

  • CLI: python run_JACKS.py --help (run from JACKS/jacks/ after clone)
  • Python: from jacks.jacks_io import runJACKS; help(runJACKS)
  • GitHub: install via git clone https://github.com/felicityallen/JACKS && cd JACKS/jacks && pip install . (setup.py is in jacks/, not the repo root; the PyPI jacks is an unrelated package)

If code throws ImportError, AttributeError, or TypeError, introspect the installed package and adapt the example to match the actual API rather than retrying.

JACKS CRISPR Screen Analysis

"Analyze CRISPR screens with guide-level efficacy modeling" -> Jointly model per-sgRNA log-fold-change across one or more screens as the product of gene essentiality and guide efficacy, sharing efficacy across screens with the same library so that low-quality guides are down-weighted automatically.

  • CLI: python run_JACKS.py countfile replicatefile guidemappingfile [options] (run from JACKS/jacks/ after clone)
  • Python: from jacks.jacks_io import runJACKS for programmatic use; lower-level from jacks.infer import inferJACKS
  • Output: per-gene effect (Gene + one column per cell line) with a matching posterior-std file, per-sgRNA efficacy (sgrna, X1, X2); p-values only with --ctrl_genes (see below)

The JACKS Model (under the hood)

Why this matters for postdoc-level use: JACKS decomposes the observed per-sgRNA log-fold-change as:

LFC[i, c] = gene_effect[g(i), c] * guide_efficacy[i] + noise

where i is sgRNA index, c is screen condition, g(i) is the gene targeted by sgRNA i. Gene effect varies by condition (different cell lines, different treatments) but guide efficacy is intrinsic to the sgRNA sequence and is treated as constant across screens. The model fits both parameters via variational Bayes with hierarchical priors:

  • guide_efficacy[i] ~ Normal(1, 1) (Gaussian prior, mean 1, variance 1; mu0_x, var0_x in jacks.infer.inferJACKSGene), shared across all sgRNAs
  • gene_effect[g, c] ~ Normal(0, 1e4) per condition (effectively flat; mu0_w, var0_w), unless apply_w_hp replaces it with a prior fitted to that gene's effects across conditions
  • a per-observation noise precision tau whose prior weight is tau_prior_strength=0.5

The variational posterior gives expected guide efficacy and gene effect. Gene-level p-values are not a likelihood-ratio test: they compare each gene's effect with pseudo-genes built by resampling the guides of supplied negative-control genes (--ctrl_genes plus n_pseudo > 0).

Initialisation is fixed (efficacy = 1, gene effect = median LFC) and nothing in the inference is random, so gene effects and efficacies are identical across reruns on the same input. Only the pseudo-gene p-values use Python's random; call random.seed(<int>) before runJACKS to make them reproducible (checked on JACKS 0.2: two unseeded runs give different p-value files, two seeded runs match byte for byte).

Critical assumption: Guide efficacy is treated as cell-line independent within the same chemistry. Allen 2019 reports per-sgRNA Cas9 KO efficacy is consistent across randomly selected batches of cell lines (within-chemistry), supporting library-shared efficacy. However, efficacy is NOT shareable across chemistries: Cas9 KO efficacy != CRISPRi knockdown efficiency != CRISPRa activation efficiency. JACKS must be run separately per chemistry; use only within the same chemistry on the same library.

When JACKS Outperforms MAGeCK and BAGEL2

Scenario Advantage Expected gain (Allen 2019)
Multi-screen joint analysis (>=3 screens with same library) Efficacy shared; noise averaged ~21% lower error vs MAGeCK; 9% vs original BAGEL; 91-99% of cell lines improved (method-dependent)
Reusing public reference screens (DepMap, Project Score) as efficacy prior Transfer learning New screens can be smaller; efficacy priors transfer across same-library screens
Libraries with broad efficacy variance (e.g. older GeCKOv2) Down-weights known weak guides Larger gain than on Brunello (already efficacy-filtered)
Heterogeneous quality (mixed plasmid quality across screens) Per-screen noise estimation Cleaner per-condition gene effects

When JACKS Is Not the Right Tool

  • Single screen, no prior efficacy: JACKS has nothing to leverage; MAGeCK or BAGEL2 work as well.
  • Single timepoint / two-condition essentiality: RRA or BAGEL2 simpler and equivalent.
  • Heavy-selection drug screens: drugZ explicit for chemogenomic; JACKS less sensitive.
  • Cancer-cell-line copy-number screens: Chronos preferred; jointly models CN bias + screen quality; JACKS does neither.
  • Cross-chemistry sharing (e.g. CRISPRi + Cas9): Efficacy is chemistry-specific; do not share.

Run JACKS Joint Analysis

Goal: Jointly analyze multiple CRISPR screens performed with the same library and chemistry.

Approach: Provide a count matrix with all samples across all screens, a replicate map identifying which samples belong to which screen and condition, and a sgRNA-to-gene map. JACKS learns guide efficacy shared across screens and gene effects per screen.

# Programmatic invocation
from jacks.jacks_io import runJACKS

# Input file paths
counts_path = 'counts.txt'                    # rows=sgRNA; first cols 'sgRNA' (or custom), then sample counts
replicate_map_path = 'replicatemap.txt'       # tab-separated with header: Replicate, Sample, Control
guide_map_path = 'guidemap.txt'               # tab-separated with header: sgRNA, Gene

# Replicate map format (tab-separated WITH header; column names match flags below)
# Replicate                Sample          Control
# Screen1_T1               Screen1_T       Screen1_C
# Screen1_T2               Screen1_T       Screen1_C
# Screen1_C1               Screen1_C       Screen1_C
# Screen2_T1               Screen2_T       Screen2_C
# Screen2_T2               Screen2_T       Screen2_C
# Screen2_C1               Screen2_C       Screen2_C

runJACKS(
    countfile=counts_path,
    replicatefile=replicate_map_path,
    guidemappingfile=guide_map_path,
    rep_hdr='Replicate',
    sample_hdr='Sample',
    ctrl_sample_hdr='Control',                # per-sample control specification
    sgrna_hdr='sgRNA',
    gene_hdr='Gene',
    outprefix='jacks_out',
    apply_w_hp=False,                         # the default and the tool's recommendation; see the variant below
    # For a p-value file add ctrl_genes='NEGv1.txt' AND n_pseudo=2000: the Python API defaults
    # n_pseudo=0 (the CLI defaults to 2000), and with n_pseudo=0 no p-value file is written.
)

Variant: hierarchical gene-effect prior (deliberate use only). apply_w_hp=True (CLI --apply_w_hp) re-fits the gene-effect prior to each gene's effects across conditions, shrinking them towards each other. The JACKS help marks it "not recommended, use with caution", and it changes rankings materially: on JACKS' own 13-cell-line Project Score example, per-line Spearman rho between the two settings was 0.75-0.89. Use it only when you intend cross-condition shrinkage, and report which setting you used.

# Equivalent CLI run (run from JACKS/jacks/ after clone; --apply_w_hp stays off)
# --ctrl_sample_hdr names a per-sample control column; use --common_ctrl_sample <name> for one shared control
python run_JACKS.py \
    counts.txt \
    replicatemap.txt \
    guidemap.txt \
    --rep_hdr Replicate \
    --sample_hdr Sample \
    --ctrl_sample_hdr Control \
    --sgrna_hdr sgRNA \
    --gene_hdr Gene \
    --outprefix jacks_out
# Outputs:
#   jacks_out_gene_JACKS_results.txt      gene effect: header `Gene` + one column per cell line
#   jacks_out_gene_std_JACKS_results.txt  matching posterior std per gene per cell line
#   jacks_out_gene_pval_JACKS_results.txt p-values (only with --ctrl_genes; the CLI's --n_pseudo defaults to 2000)
#   jacks_out_grna_JACKS_results.txt      sgRNA-level: header `sgrna`, `X1`, `X2`
#   jacks_out_JACKS_results_full.pickle  full posterior for downstream

Output Interpretation

Column Meaning Direction
X1 (gene file) Posterior mean of gene_effect Negative = essential (depleted); positive = enriched
gene std file Posterior std of the gene effect Lower = more confident; combine as effect/std for a z-like statistic
X1 (sgRNA file) Posterior mean of guide efficacy Centred near 1 and unbounded; the reference Avana set spans negative values to >100
X2 (sgRNA file) Second moment E(X^2) of efficacy; std = sqrt(X2 - X1^2) Confidence in the efficacy estimate

Interpretation rule: A gene is essential if its effect is negative and large relative to its posterior std: divide each cell-line column of the gene file by the same column of the gene std file; effect/std < -2 is roughly a 95% credible deviation from zero. The gene file has no X1/X2 columns. Those belong to the sgRNA file, where X2 is a second moment, not a std. Supply --ctrl_genes (with n_pseudo > 0 in Python) to also get a p-value file. Sort by effect (most negative first) for essentiality rank.

Build Library-Wide Efficacy Prior from Reference Screens

Goal: Transfer learned efficacy from a large public screen panel to a new small screen.

Approach: Run JACKS on the reference panel (e.g. DepMap CRISPR screens with TKOv3 or Brunello), extract per-sgRNA efficacy posterior, and supply it as the prior for a new screen.

def extract_efficacy_prior(reference_jacks_results):
    '''Build per-sgRNA efficacy prior (mean + std) from a large reference screen.'''
    df = pd.read_csv(reference_jacks_results, sep='\t')
    prior = df[['sgrna', 'X1', 'X2']]      # --reffile requires these exact column names; do not rename
    return prior

# Use in new JACKS run via --reffile <path>
# Reference: Allen 2019 Genome Research 29:464; efficacy-aware testing enables ~2.5x smaller screens (fewer replicates/guides)

Per-sgRNA Efficacy Diagnostics

Goal: Identify low-efficacy guides for library refinement.

Approach: Examine the distribution of inferred efficacies; guides below 0.3 are likely non-functional and should be excluded from re-designed libraries.

import pandas as pd

def efficacy_summary(grna_results_path, guidemap_path, low_threshold=0.3,
                     sgrna_hdr='sgRNA', gene_hdr='Gene'):
    '''Summarise per-sgRNA efficacy. The grna file has only sgrna/X1/X2, so genes come from the guide map.'''
    df = pd.read_csv(grna_results_path, sep='\t')
    guidemap = pd.read_csv(guidemap_path, sep='\t', usecols=[sgrna_hdr, gene_hdr])
    df = df.merge(guidemap, left_on='sgrna', right_on=sgrna_hdr, how='left')
    unmapped = df[gene_hdr].isna().sum()
    if unmapped:
        raise ValueError(f'{unmapped} sgRNAs in the results are absent from the guide map; check naming')
    df['low_eff'] = df['X1'] < low_threshold
    summary = {
        'total_guides': len(df),
        'low_efficacy_count': int(df['low_eff'].sum()),
        'low_efficacy_pct': df['low_eff'].mean() * 100,
        'median_efficacy': df['X1'].median(),
        'q25_q75': (df['X1'].quantile(0.25), df['X1'].quantile(0.75)),
    }
    # Per-gene proportion of low-efficacy guides
    by_gene = df.groupby(gene_hdr)['low_eff'].mean().sort_values(ascending=False)
    summary['genes_with_all_low_eff'] = int((by_gene == 1).sum())  # genes where every guide is weak
    return summary, by_gene

Critical: Genes where every guide is low-efficacy will show no signal regardless of biology. Filter from interpretation; flag for re-design with updated rules (Brunello / TKOv3).

Comparing JACKS, MAGeCK, BAGEL2

Property JACKS MAGeCK BAGEL2
Statistical framework Variational Bayes NB GLM + alpha-RRA / MLE Bayes factor on per-sgRNA fold change
Models guide efficacy Yes (jointly) No (optional fixed input) No
Multi-screen joint Yes (native) Limited (MLE design matrix) No (per-screen)
Speed Slow (variational inference) Fast Fast
Output gene effect + sgRNA efficacy beta or RRA score Bayes Factor
Best for Multi-screen joint analyses, library calibration General-purpose, single screen Essentiality classification
Quantified accuracy gain (Allen 2019) ~21% lower error vs MAGeCK; 9% vs BAGEL v1 Reference Not benchmarked (Allen 2019 compared BAGEL v1)

Reconciliation: Hits identified by JACKS AND MAGeCK are high confidence. JACKS-only hits typically reflect strong gene signals where one or two guides were dragging down MAGeCK; verify the up-weighted high-efficacy guides have the expected sign. MAGeCK-only hits at FDR <0.05 may be single-guide outliers; check sgrna_summary for guide-level dispersion.

Failure Modes

Efficacy collapsed near zero for all guides

Trigger: Screen used a chemistry the model doesn't support (e.g., CRISPRi screen analyzed with JACKS defaults). Mechanism: CRISPRi efficacy is fundamentally different from Cas9-KO efficacy; the Gaussian efficacy prior (mean 1, variance 1) assumes Cas9-KO-like guides. Symptom: Median efficacy <0.2; almost no significant gene effects. Fix: Do not reuse Cas9-KO efficacies or --reffile priors. If a CRISPRi/a reference panel with the same library exists, run JACKS on it and pass its grna file via --reffile. Neither the CLI nor runJACKS() exposes the prior hyperparameters; they are keyword arguments of jacks.infer.inferJACKSGene (mu0_x, var0_x, mu0_w, var0_w, tau_prior_strength), which inferJACKS looks up at call time, so they can be overridden for one run:

import functools
import jacks.infer
from jacks.jacks_io import runJACKS

_default_gene_fit = jacks.infer.inferJACKSGene
# Example: a weaker efficacy prior (larger var0_x) for a chemistry whose efficacies are not centred on 1.
# Choose values from a matched reference run, not by tuning until hits appear.
jacks.infer.inferJACKSGene = functools.partial(_default_gene_fit, mu0_x=1.0, var0_x=4.0)
try:
    runJACKS('counts.txt', 'replicatemap.txt', 'guidemap.txt', outprefix='jacks_crispri', ctrl_sample_hdr='Control')
finally:
    jacks.infer.inferJACKSGene = _default_gene_fit   # restore for later runs in this session

This relies on JACKS 0.2 internals, not a public API; re-check help(jacks.infer.inferJACKSGene) on other versions.

Cross-cell-line efficacy disagreement

Trigger: Pooling screens across cell lines with very different Cas9 expression / chromatin / fitness baselines. Mechanism: Efficacy depends on Cas9 expression and chromatin accessibility; sharing across lines averages real per-line differences. Symptom: Per-line gene effects look noisier than per-line MAGeCK results. Fix: Use Chronos for multi-cell-line screens with screen-quality modeling; reserve JACKS for screens with matched chemistry + cell type / culture conditions.

MCMC / variational convergence failure

Trigger: A gene's variational updates hit the iteration cap before the lower bound settles (few guides, conflicting guides, very noisy replicates). Mechanism: Each gene is fitted for at most n_iter=50 updates and stops early once the lower bound changes by < tol=0.1; a gene still moving at iteration 50 is returned as-is. Symptom: Not run-to-run variation -- inference is deterministic, so reruns on identical input give identical effects. Instead, effects shift when you change n_iter, and the DEBUG log (Iter 50/50 ...) shows genes ending at the cap. Fix: The CLI and runJACKS() expose no iteration argument. Refit with a higher cap and compare: jacks.jacks_io.inferJACKS = functools.partial(jacks.infer.inferJACKS, n_iter=500) before runJACKS, then restore it; genes whose effect/std changes sign or crosses -2 were not converged. Adding guides per gene or screens also helps.

sgRNA-to-gene map mismatch

Trigger: Guide map and count matrix use different sgRNA naming conventions (e.g. BRCA1_1 vs BRCA1.1). Mechanism: JACKS builds a sgRNA-to-gene dictionary from the map and keeps only guides found in it; unmatched guides are dropped, not set to NaN. Symptom: Genes missing from the output rows entirely (no NaN values appear). Fix: Standardize naming; sanity check len(jacks_output) == n_genes_expected.

Reference efficacy prior from wrong library

Trigger: Using DepMap Brunello efficacy as prior for a screen with a custom TKOv3-style library. Mechanism: Per-sgRNA efficacy is sequence-specific; sgRNAs in one library map to different gene contexts than another. Symptom: Usually an immediate exception, <sgRNA> has no sgrna reference in <reffile>, because JACKS 0.2 requires every guide in the map to be in the reference. That check is by ID only: if the IDs happen to match (e.g. both renamed GENE_1, GENE_2) the run succeeds silently with the wrong efficacies. Fix: Match library exactly, by sequence and not only by ID; if no matched reference exists, run without prior.

Reconciliation: When JACKS and Other Tools Disagree

Pattern Likely cause Action
JACKS significant, MAGeCK not One low-efficacy guide dragged MAGeCK; JACKS down-weighted it Trust JACKS if 3+ high-efficacy guides agree
MAGeCK significant, JACKS not All guides have similar efficacy; JACKS prior shrinks signal Verify per-guide LFC consistency in MAGeCK sgrna_summary
JACKS efficacy ~0.5 for all guides Efficacy prior mismatched to the chemistry, or weak signal overall (--apply_w_hp acts on gene effects, not efficacy) Confirm chemistry and library match; see "Efficacy collapsed near zero" for a matched --reffile or prior override
Gene effect different sign from MAGeCK Multi-screen pooling created mean effect different from single-screen Run per-screen separately to confirm

Quantitative Thresholds

Threshold Value Source / Rationale
Hit call gene effect negative with abs(effect/std) > 2 Bayesian z-equivalent; p-values need --ctrl_genes
Effective gene signal effect < 0 AND abs(effect/std) > 2, from the gene and gene std files Bayesian z-equivalent
Low-efficacy guide flag X1 (sgRNA) <0.3 Operational convention; below this, guide likely non-functional
Reference for prior reuse DepMap or Project Score panel Established efficacy distribution
Minimum screens for joint efficacy benefit 3+ Below this, single-screen tools (MAGeCK/BAGEL2) equivalent
Iterations for variational inference at most 50 per gene, early stop at lower-bound change < 0.1 (JACKS 0.2) Not exposed on the CLI; see convergence failure mode
Cross-library efficacy transfer Not supported Different libraries -> different sequences -> different efficacies
Cross-chemistry efficacy transfer Not supported Cas9 efficacy != CRISPRi efficacy

Common Errors

Error / symptom Cause Solution
Genes missing from output sgRNA-to-gene map mismatch (unmatched guides are dropped) Verify naming consistency; check len(gene_results) == n_genes_expected
Median efficacy <0.2 Wrong chemistry assumed by prior Use a matched-chemistry --reffile or override the efficacy prior (see Failure Modes)
Lower bound still changing at Iter 50/50 in the DEBUG log Iteration cap reached Refit with a higher n_iter (see Failure Modes) and compare effects
p-values differ between runs Pseudo-genes are sampled with Python random random.seed(<int>) before runJACKS; gene effects themselves are deterministic
<sgRNA> has no sgrna reference in <reffile> --reffile from a different library Match library exactly
Library-reuse prior doesn't help Reference IDs match but sequences or context differ Match library by sequence

References

  • Allen F et al. 2019. Genome Research 29:464. JACKS; original Bayesian joint analysis paper.
  • Allen F, Parts L (Wellcome Sanger Institute). https://github.com/felicityallen/JACKS. Official repository.
  • Behan FM et al. 2019. Nature 568:511. Project Score CRISPR panel; library-wide reference screen data.
  • Meyers RM et al. 2017. Nat Genet 49:1779. Avana CRISPR DepMap; reference panel for efficacy transfer.

Related Skills

  • crispr-screens/mageck-analysis - MAGeCK RRA/MLE comparison
  • crispr-screens/bagel-essentiality - Alternative for essentiality without efficacy modeling
  • crispr-screens/library-design - sgRNA design rules informed by JACKS efficacy output
  • crispr-screens/copy-number-correction - Chronos preferred for cancer-line multi-screen analyses
  • crispr-screens/screen-qc - Pre-JACKS QC; replicate Pearson must pass before joint analysis
  • crispr-screens/hit-calling - Cross-method decision tree
  • crispr-screens/batch-correction - JACKS does not adjust for batch; pre-correct if necessary

04 同仓库更多 Skills

mrsonord2240
mrsonord2240/openscience-specialists

bio-workflows-metabolomics-pipeline

Orchestrates the untargeted LC-MS metabolomics pipeline end-to-end (xcms 4.x feature extraction, QC/drift/normalization, confidence-stratified annotation, permutation-validated statistics, background-aware pathway mapping), naming what each stage decides and where it silently fails. Use when running a full LC-MS metabolomics study from raw mzML to enriched pathways and needing the honest handoffs between stages. Each stage defers to its component skill for parameters and traps; for stable-isotope flux (a separate branch, not this untargeted flow) see metabolomics/isotope-tracing.

★ 2
mrsonord2240
mrsonord2240/openscience-specialists

bio-metabolomics-xcms-preprocessing

Programmatic untargeted LC-MS feature extraction in R with the modern xcms 4.x MsExperiment/XcmsExperiment API, taking raw mzML to a feature table via CentWave peak detection, retention-time alignment, peak-density correspondence, gap-filling, CAMERA redundancy collapse, and built-in QC feature filtering. Use when converting centroided LC-MS runs into a features-by-samples matrix and deciding centWave/grouping/alignment parameters. For drift correction and QC/CV filtering execution see metabolomics/normalization-qc; for metabolite identification see metabolomics/metabolite-annotation; for the MS-DIAL GUI alternative with MS2Dec deconvolution see metabolomics/msdial-preprocessing; for downstream statistics see metabolomics/statistical-analysis.

★ 2
mrsonord2240
mrsonord2240/openscience-specialists

bio-metabolomics-statistical-analysis

Decision-grade statistical analysis for metabolomics intensity tables. Covers transformation and scaling (Pareto vs unit-variance as a hidden hypothesis), unsupervised structure (PCA/HCA for QC), permutation-validated PLS-DA/OPLS-DA (R2 vs Q2, double CV, VIP as heuristic), univariate testing (Welch/Mann-Whitney/ANOVA/LMM with covariate adjustment), and dependence-aware multiple testing. Use when testing which metabolites differ, building or validating a discriminant model, choosing a scaling, or correcting many correlated tests. For sample-wise normalization/drift correction see metabolomics/normalization-qc; for ML classifiers and selection-inside-CV leakage see machine-learning/biomarker-discovery and machine-learning/model-validation; for pathway interpretation see metabolomics/pathway-mapping; for design/power/multiplicity regime see experimental-design/multiple-testing.

★ 2
mrsonord2240
mrsonord2240/openscience-specialists

bio-metabolomics-pathway-mapping

Maps metabolomics results to biological pathways via over-representation (ORA), metabolite-set enrichment (MSEA/QEA), mummichog/PSEA on raw m/z peaks, and network-diffusion enrichment (FELLA), with correct background-set construction and honest interpretive ceilings. Use when interpreting differential metabolites or an untargeted LC-MS feature table in pathway context, choosing ORA vs MSEA vs mummichog vs topology, or setting the reference/background set. For annotation confidence levels feeding ORA see metabolomics/metabolite-annotation; for gene-set concepts see pathway-analysis/go-enrichment and pathway-analysis/gsea; for joint gene+metabolite pathways see multi-omics-integration/mofa-integration.

★ 2
mrsonord2240
mrsonord2240/openscience-specialists

bio-metabolomics-normalization-qc

Designs QC, corrects signal drift, removes batch effects, filters features, normalizes samples, and imputes missing values for untargeted LC-MS/GC-MS metabolomics, framing each step as a measurement model that can create or erase biological signal. Use when processing a peak/feature table before statistical analysis, choosing a drift-correction or sample-normalization method, deciding QC RSD vs D-ratio filtering, or handling left-censored missing values. The feature table is produced by metabolomics/xcms-preprocessing or metabolomics/msdial-preprocessing; transformation/scaling for modeling defers to metabolomics/statistical-analysis; cross-study design issues link to experimental-design/batch-design.

★ 2
mrsonord2240
mrsonord2240/openscience-specialists

bio-metabolomics-msdial-preprocessing

Runs the MS-DIAL preprocessing workflow (peak picking, MS2Dec spectral deconvolution, alignment, gap-filling) and imports the alignment-result table into R or Python with honest filtering. Use when preprocessing LC-MS DDA/DIA (SWATH) or GC-MS raw data with MS-DIAL, deciding MS-DIAL vs XCMS, configuring the MSDIALCUI console run, or parsing an MS-DIAL export into a clean feature matrix. For programmatic R peak detection and the feature-table-as-artifact framing see metabolomics/xcms-preprocessing; for lipid annotation mode see metabolomics/lipidomics; for MSI-level confidence honesty see metabolomics/metabolite-annotation; for drift correction and QC see metabolomics/normalization-qc.

★ 2